ACM
NRIX icon

Aster Capital Management’s Nurix Therapeutics NRIX Stock Holding History

Aster Capital Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.27K Buy
275
+271
+6,775% +$4.49K ﹤0.01% 720
2025
Q4 		$76 Buy
+4
New +$57 ﹤0.01% 1045
2025
Q2 		– Sell
-833
Closed -$12.9K – 1403
2025
Q1 		$12.9K Buy
833
+595
+250% +$9.95K ﹤0.01% 1037
2024
Q4 		$4.48K Buy
+238
New +$5.46K ﹤0.01% 872

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Aster Capital Management's NRIX Position: Q1 2026 in Review

Aster Capital Management increased its Nurix Therapeutics (NRIX) stake by 6,775% in Q1 2026, buying an estimated $4.49K and bringing the position to 275 shares worth $3.27K. The position accounts for ﹤0.01% of the portfolio, ranked #720.

Aster Capital Management first reported a position in NRIX in Q4 2024 and has held it in 4 quarters since. The position peaked at $12.9K in Q1 2025. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Aster Capital Management held 275 shares of Nurix Therapeutics worth $3.27K as of Q1 2026.
  • Aster Capital Management bought 271 Nurix Therapeutics shares in Q1 2026, an estimated $4.49K.
  • Nurix Therapeutics made up ﹤0.01% of Aster Capital Management's portfolio in Q1 2026, its #720 holding.
  • Aster Capital Management first reported a position in Nurix Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • Aster Capital Management's Nurix Therapeutics position peaked at $12.9K in Q1 2025.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Aster Capital Management's 13F filing for Q1 2026, filed 13 May 2026.